SCHEMBL3076298

SCHEMBL3076298

Cc1nn(Cc2nc(C#N)cs2)c(C)c1-c1ccc(C#N)cc1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.40
GAA P10253 2/20 0.39
CRHR1 P34998 1/20 0.38
CYP11B2 P19099 2/20 0.37
AR P10275 5/20 0.37
SLC2A1 P11166 1/20 0.36
SLC2A3 P11169 1/20 0.36
SLC2A4 P14672 1/20 0.36
BRD4 O60885 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
RECQL P46063 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
EGLN2 Q96KS0 1/20 0.33
CNR1 P21554 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3081369 0.84 MAPK1 (0.43) MAPK1GAAARPTGDR2MAPT
SCHEMBL3086088 0.83 AR (0.44) CYP11B2ARSLC2A1SLC2A3SLC2A4
SCHEMBL3086581 0.83 MAPK1 (0.42) MAPK1ARSLC2A1SLC2A3SLC2A4
SCHEMBL3069269 0.80 ALDH1A1 (0.52) MAPK1GAAARMEN1MAPT
SCHEMBL3085330 0.79 AR (0.50) GAACYP11B2ARSLC2A1PTGDR2
SCHEMBL3080496 0.75 AR (0.50) CYP11B2ARBRD4PTGDR2CNR1
SCHEMBL3073239 0.75 AR (0.41) GAACRHR1CYP11B2ARBRD4
SCHEMBL5361962 0.74 MAPT (0.43) MAPK1GAACYP11B2ARMEN1
SCHEMBL3070156 0.73 SLC2A1 (0.53) GAACYP11B2ARSLC2A1SLC2A3
SCHEMBL6468898 0.73 AR (0.64) MAPK1CYP11B2ARMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101842357-A Substituted pyrazole derivatives TAKEDA PHARMACEUTICAL 2010-09-22 CN disclosed
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
EP-2194045-A1 SUBSTITUTED PYRAZOLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2010-06-09 EP disclosed
EP-2194045-A1 SUBSTITUTED PYRAZOLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2010-06-09 EP disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE AR, NR5A1, NR3C2 MAPK1 1215/4885GAA 4868/4885CRHR1 52/4885
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES AR, NR5A1, NR3C2 MAPK1 1174/4885GAA 4868/4885CRHR1 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.